Smart bomb chemo shows promise against tough lymphoma

NCT ID NCT03113500

First seen Nov 15, 2025 · Last updated Apr 28, 2026 · Updated 22 times

Summary

This study tested a new combination of drugs for people with a rare type of blood cancer called CD30-positive peripheral T-cell lymphoma. The treatment pairs a targeted antibody-drug (brentuximab vedotin) with standard chemotherapy. 48 adults took part to see how well the combo works and what side effects occur. The goal was to shrink or eliminate the cancer after initial treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • BCCA-Vancouver Cancer Centre

    Vancouver, British Columbia, V5Z 4E6, Canada

  • City of Hope Comprehensive Cancer Center

    Duarte, California, 91010, United States

  • Hackensack University Medical Center

    Hackensack, New Jersey, 07601, United States

  • M D Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio, 43210, United States

Conditions

Explore the condition pages connected to this study.